Candel director receives 4,618 stock options
Candel Therapeutics director Paul B. Manning received a stock option grant covering 4,618 shares of Common Stock.
Accepted by SEC EDGAR
Learn about SEC filing dates
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Candel Therapeutics director Paul B. Manning received a stock option grant covering 4,618 shares of Common Stock. The options have an exercise price of $4.90 per share, were fully vested at the time of grant, and expire on March 31, 2036. According to the filing, this award was given in lieu of normal quarterly cash payments, and following the grant he holds options for 4,618 shares directly.
Insider Trade Summary
Grant/Award: 4,618 shares
Grant/Award
1 txn
Insider
Manning Paul B
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 4,618 | $4.114 | $19K |
Holdings After Transaction:
Stock Option (Right to Buy) — 4,618 contracts (Direct)
Holdings Before and After:
Stock Option (Right to Buy), 0 to 4,618 contracts (Direct)
Footnotes (1)
- F1. This award has been granted in lieu of normal quarterly cash payments. The underlying award quantity is fully vested at time of grant.
Key Figures
Option grant size: 4,618 options
Exercise price: $4.90 per share
Grant valuation reference: $4.1140 per option
+3 more
6 metrics
Option grant size
4,618 options
Stock Option (Right to Buy) underlying Common Stock shares granted
Exercise price
$4.90 per share
Conversion or exercise price of the stock options
Grant valuation reference
$4.1140 per option
Transaction price per derivative security reported for the award
Options after transaction
4,618 options
Total derivative securities beneficially owned following transaction
Exercise date
April 1, 2026
Exercise date associated with the stock option award
Expiration date
March 31, 2036
Expiration of the stock option (Right to Buy)
Key Terms
Stock Option (Right to Buy), grant/award acquisition, derivative securities, Common Stock, +1 more
5 terms
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
grant/award acquisition financial
"transaction_action: grant/award acquisition"
derivative securities financial
"derivativeTransactionCount for all derivative-type records"
Financial contracts whose value is tied to the price or performance of another asset, such as a stock, bond, commodity, index, or currency; examples include options, futures and swaps. They matter to investors because they let you protect against price swings, bet on future moves or gain larger exposure with less upfront cash—like using a lever or insurance policy on an investment—so they can amplify gains and losses and help manage portfolio risk.
Common Stock financial
"underlying_security_title: Common Stock"
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
fully vested at time of grant financial
"The underlying award quantity is fully vested at time of grant"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Candel Therapeutics (CADL) report for Paul B. Manning?
Candel Therapeutics reported that director Paul B. Manning received a grant of stock options for 4,618 shares of Common Stock. The grant is recorded as an acquisition under a compensation award, not an open-market purchase or sale of existing shares.
How many stock options did the Candel Therapeutics director receive in this Form 4?
The director received a stock option award for 4,618 underlying shares of Candel Therapeutics Common Stock. These options were fully vested at the time of grant and represent his entire option position shown, with 4,618 derivative securities held following the transaction.
What is the exercise price and expiration date of the CADL stock options granted?
The stock options granted to the director have an exercise price of $4.90 per share and an expiration date of March 31, 2036. This means he can choose to buy shares at $4.90 any time before that expiration, subject to plan terms.
Was the Candel Therapeutics (CADL) option grant part of regular compensation?
Yes. The footnote states the award was granted in lieu of normal quarterly cash payments. This indicates the stock option grant functions as a form of routine director compensation rather than a discretionary open-market trade, and the options were fully vested when granted.
AI-generated analysis. How Rhea-AI works. Not financial advice.
